Physician profile
Rashmi Acharya
NPI 1871538405
$2,011.12
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,692 · 2020: $61.22 · 2021: $13.42 · 2022: $38.98 · 2023: $189 · 2024: $15.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $205.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celularity INC. | $1,634.00 | 2019 | |
| Medtronic, INC. | $75.96 | 2023 | Truclear |
| Exact Sciences Corporation | $42.09 | 2023 | Cologuard Collection Kit |
| Coopersurgical, INC. | $41.67 | 2019-2023 | Paragard T 380a |
| Sumitomo Pharma America, INC. | $41.63 | 2023 | Myfembree |
| Hologic Sales and Service, LLC | $28.79 | 2022-2024 | Aptima |
| Mayne Pharma Commercial LLC | $27.94 | 2022-2023 | |
| Abbvie INC. | $27.70 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.83 | 2020 | |
| Roche Diagnostics Corporation | $18.25 | 2019 | |
| Avion Pharmaceuticals | $13.42 | 2021 | |
| Exeltis, USA INC. | $13.41 | 2020 | |
| Daiichi Sankyo INC. | $13.13 | 2020 | |
| Amag Pharmaceuticals, INC. | $12.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rashmi Acharya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.